神经递质系统基因变异作为重复经颅磁刺激和选择性5-羟色胺再摄取抑制剂治疗强迫症疗效的生物标志物。

Neurotransmitter system gene variants as biomarkers for the therapeutic efficacy of rTMS and SSRIs in obsessive-compulsive disorder.

作者信息

Chu Lingjun, Wu Yidan, Yin Jiajun, Zhang Kai, Zhong Yiwen, Fan Xiwang, Wang Guoqiang

机构信息

Clinical Research Center for Mental Disorders, Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University, Shanghai, China.

Brain Science Basic Laboratory, The Affiliated Wuxi Mental Health Center of Jiangnan University, Wuxi Central Rehabilitation Hospital, Wuxi, Jiangsu, China.

出版信息

Front Psychiatry. 2024 May 22;15:1350978. doi: 10.3389/fpsyt.2024.1350978. eCollection 2024.

DOI:10.3389/fpsyt.2024.1350978

PMID:38840948

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11150660/

Abstract

PURPOSE

This study aims to examine the potential influence of RS4680 (), RS16965628 (), and RS1019385 () polymorphisms on the therapeutic response to repetitive transcranial magnetic stimulation (rTMS) and selective serotonin reuptake inhibitors (SSRIs) in individuals with obsessive-compulsive disorder (OCD).

PATIENTS AND METHODS

Thirty-six untreated outpatients diagnosed with OCD were recruited and allocated to active or sham rTMS groups for two weeks. The mean age of the participants was 31.61, with 17 males (47.22%) and 19 females (52.78%). Peripheral blood samples (5 mL) were collected from each participant using ethylenediaminetetraacetic acid (EDTA) vacuum tubes for genotyping purposes, clinical evaluation was taken place at baseline and second week.

RESULTS

The A allele of RS4680, C allele of RS16965628, and GG allele of RS1019385 were identified as potential bio-markers for predicting treatment response to OCD treatments (rTMS & SSRIs).

CONCLUSION

Those genes may serve as bio-markers for the combined treatment of rTMS and SSRIs in OCD. The finding hold promise for further research and the potential implementation of precision treatment of OCD.